What is the Global market size of the Viral Clearance Market?

Global Viral Clearance Market size was valued at USD 492.9 billion in 2021 and is poised to grow from USD 535.6 billion in 2022 to USD 1519.7 billion by 2030, growing at a CAGR of 16.1% in the forecast period (2023-2030).

What is the key driver of the Global Viral Clearance Market?

The product safety procedures include the assessment of viral safety. Particularly for IND and BLA approvals, regulatory bodies place a strong emphasis on viral safety and demand high-quality data in support. Expertise in the key areas of these processes, and familiarity with the regulatory requirements and the process itself are crucial for strategic planning and can result in time, effort, and financial savings.

Top Viral Clearance Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Viral Clearance Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Viral Clearance industry players.

Viral Clearance Market Competitive Landscape

Viral Clearance Market Top Players Company Profiles

Charles River Laboratories International, Inc.
Merck KGaA
Wuxi AppTec Inc.
Eurofins Scientific
Avance Biosciences Inc.
Lonza Group AG
Sigma-Aldrich Corporation
Sartorius AG
Texcell, Inc.
Kedrion Biopharma Inc.
ViruSure GmbH
Clean Cells Inc.
Cytovance Biologics Inc.
GE Healthcare Life Sciences
Vironova AB
F. Hoffmann-La Roche Ltd.
BSL Bioservice Scientific Laboratories GmbH
Nelson Laboratories LLC
BioReliance Corporation
Novartis AG

Viral Clearance Market Recent Development

In June 2022, Asahi Kasei Medical is expanding into the CDMO business with the acquisition of Bay Area biologics maker Bionova Scientific for an undisclosed price. Like many in the industry, Japan-based Asahi Kasei has been on an expansion tear during the past few years. It purchased Austrian viral safety testing services provider Virusure Forschung und Entwicklung in 2019 and last year snapped up U.S-based mycoplasma testing services company Bionique Testing Labs.
In August 2021, WuXi Biologics announced that just 13 months after receiving its first GMP certificate, it has also received European Medicines Agency (EMA) GMP certificate for Biosafety testing center in Suzhou. This certificate demonstrates WuXi Biologics’ compliance with international cGMP safety assessment standards and regulatory guidelines.

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

Viral Clearance Market size was valued at USD 621.83 Billion in 2024 and is poised to grow from USD 721.95 Billion in 2025 to USD 2383.21 Billion by 2033, growing at a CAGR of 16.1% during the forecast period (2026–2033).

The key players in the viral clearance market are working on continuous innovation in the field of research and development and product portfolio enhancement for better therapeutic outcomes for consumers. For example, In November 2021, Wuxi biologics announced the official opening of its advanced therapies testing facility, including 140,000 sq. ft laboratories to enhance the company's Contract Testing, Developing, and manufacturing Organization businesses to meet the increasing needs of customers in cell and gene therapy industry. Companies are also focusing on mergers and acquisitions to expand their businesses. 'Charles River Laboratories ', 'Merck KGaA ', 'Texcell ', 'WuXi AppTec ', 'Sartorius AG ', 'Eurofins Scientific ', 'Vironova ', 'Syngene International ', 'Microbac Laboratories ', 'Creative Biolabs ', 'Nelson Labs ', 'SGS AG ', 'Lonza Group ', 'Bioscience Laboratories ', 'Labor Dr. Merk & Kollegen ', 'Gilead Sciences ', 'Poolbeg Pharma ', 'Incyte ', 'Genmab ', 'Biogen '

Growing Demand for Generics and Biosimilars: Increasing demand for biosimilars and generics is an ongoing trend. The need for sophisticated and cheap therapies for chronic diseases around the world is driving demand for recombinant non-glycosylation proteins in the biosimilars market; the application of cutting-edge technology to increase avenues.

In 2022, North America dominated the market by accounting for over 35% of the market share owing to the rapidly growing innovation in biotechnology and Life sciences. Growth of pharmaceuticals, increase in number of drug approvals, investments in research and development, and accuracy and flexibility of method in life sciences research has shaped the market growth in these areas. The growing prevalence of illnesses and an increased production of monoclonal antibodies, and government assistance for medication development are some of the primary reasons driving the viral clearance industry in the US with increasing pharmaceutical production supporting the growth of the region. Europe is expected to follow North America due to the strong foundation of research and development and pharmaceuticals and is expected to capture the second-largest share of the market.

Top Viral Clearance Companies

Viral Clearance Market Competitive Landscape

FAQs

What is the global market size of Viral Clearance Market?

Who are the key vendors in the Viral Clearance Market?

What is the key driver of Viral Clearance Market?

What is the key market trend for Viral Clearance Market?

Which region accounted for the largest share in Viral Clearance Market?

Request Free Customization